昆药集团
(600422)
| 流通市值：108.93亿 | | | 总市值：108.93亿 |
| 流通股本：7.57亿 | | | 总股本：7.57亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,351,347,279.45 | 1,608,452,032.42 | 8,401,447,233.37 | 5,457,454,882.94 |
| 营业收入 | 3,351,347,279.45 | 1,608,452,032.42 | 8,401,447,233.37 | 5,457,454,882.94 |
| 二、营业总成本 | 3,100,213,351.06 | 1,490,477,668.68 | 7,550,203,664.56 | 5,001,893,407.76 |
| 营业成本 | 2,015,846,300.01 | 1,014,740,498.5 | 4,750,196,536.29 | 3,224,711,276.3 |
| 税金及附加 | 34,249,303.52 | 14,112,985.06 | 81,931,448.28 | 52,889,408.55 |
| 销售费用 | 808,861,492.81 | 341,535,462.86 | 2,226,082,369.4 | 1,418,514,480 |
| 管理费用 | 174,256,035.83 | 86,280,268.09 | 371,243,797.11 | 228,950,764.83 |
| 研发费用 | 43,891,351.15 | 22,356,968.35 | 106,761,340.29 | 60,014,539.23 |
| 财务费用 | 23,108,867.74 | 11,451,485.82 | 13,988,173.19 | 16,812,938.85 |
| 其中:利息费用 | 27,472,873.34 | 13,732,056.89 | 26,361,325 | 19,629,866.98 |
| 其中:利息收入 | 4,762,912.53 | 3,344,275.54 | 12,843,782.47 | 6,642,226.89 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,445,663.76 | 194,273.91 | 6,915,856.46 | -176,072.35 |
| 加:投资收益 | -694,593.72 | -218,160.08 | 14,933,233.77 | 12,246,296.01 |
| 资产处置收益 | -757.86 | -771.95 | 1,012,610.84 | 261,494.05 |
| 资产减值损失(新) | -4,752,967.11 | -2,934,870.47 | -21,954,873.58 | -14,670,900.64 |
| 信用减值损失(新) | -7,289,627.92 | 9,095,275.76 | -45,994,595.2 | -52,062,124.86 |
| 其他收益 | 59,962,336.87 | 24,353,834.91 | 121,390,832.77 | 85,686,902.79 |
| 四、营业利润 | 299,803,982.41 | 148,463,945.82 | 927,546,633.87 | 486,847,070.18 |
| 加:营业外收入 | 2,351,220.12 | 2,067,494.82 | 3,925,293.54 | 4,508,338.29 |
| 减:营业外支出 | 3,214,933.56 | 1,427,529.21 | -3,098,310.94 | -6,150,692.16 |
| 五、利润总额 | 298,940,268.97 | 149,103,911.43 | 934,570,238.35 | 497,506,100.63 |
| 减:所得税费用 | 49,019,448.21 | 35,551,469.84 | 183,349,572.79 | 106,993,019.77 |
| 六、净利润 | 249,920,820.76 | 113,552,441.59 | 751,220,665.56 | 390,513,080.86 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 249,920,820.76 | 113,552,441.59 | 751,220,665.56 | 390,513,080.86 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 198,355,219.85 | 90,482,321.86 | 648,081,341.92 | 387,395,872.22 |
| 少数股东损益 | 51,565,600.91 | 23,070,119.73 | 103,139,323.64 | 3,117,208.64 |
| 扣除非经常损益后的净利润 | 151,101,472.65 | 72,061,426.19 | 419,206,143.36 | 289,362,242.31 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.26 | 0.12 | 0.86 | 0.51 |
| (二)稀释每股收益 | 0.26 | 0.12 | 0.86 | 0.51 |
| 八、其他综合收益 | 1,987,515.85 | 1,281,044.33 | -3,926,635.37 | -987,127.81 |
| 归属于母公司股东的其他综合收益 | 2,048,607.45 | 1,295,331.14 | -3,671,171.18 | -915,314.42 |
| 九、综合收益总额 | 251,908,336.61 | 114,833,485.92 | 747,294,030.19 | 389,525,953.05 |
| 归属于母公司股东的综合收益总额 | 200,403,827.3 | 91,777,653 | 644,410,170.74 | 386,480,557.8 |
| 归属于少数股东的综合收益总额 | 51,504,509.31 | 23,055,832.92 | 102,883,859.45 | 3,045,395.25 |
| 公告日期 | 2025-08-16 | 2025-04-29 | 2025-03-12 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |